angiostatin

Angiostatin is a naturally occurring protein fragment that inhibits angiogenesis, the process by which new blood vessels are formed. It is derived from the larger protein plasminogen, which is involved in blood clot breakdown. Angiostatin is a potent inhibitor of endothelial cell proliferation, migration, and tube formation, all of which are crucial steps in angiogenesis.

The discovery of angiostatin by Dr. Judah Folkman and his colleagues in the 1990s generated significant interest in its potential as an anti-cancer therapeutic. Tumors require a constant supply of nutrients and oxygen to grow, which they obtain through the formation of new blood vessels. By inhibiting angiogenesis, angiostatin could theoretically starve tumors and prevent their growth and spread.

Research into angiostatin has focused on its mechanisms of action and its potential clinical applications. It is thought to interact with several cell surface receptors on endothelial cells, disrupting signaling pathways that promote blood vessel growth. While initial studies showed promise, translating these findings into effective human cancer treatments has faced challenges, including issues with delivery, stability, and efficacy. Despite these hurdles, research continues to explore angiostatin and its derivatives as part of combination therapies for various cancers. Its role as a naturally occurring inhibitor of blood vessel formation continues to be a subject of scientific investigation.